Method of treatment or improvement of mucocutaneous or ocular toxicities.

摘要

A pharmaceutical composition comprising a therapeutically effective amount of a histone deacetylase inhibitor (HDAC) and / or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of mucocutaneous or ocular toxicities or side effects resulting from blocking cell growth and survival signal transduction pathways produced by an inhibitor of EGFR (epidermal growth factor receptor), in which the HDAC inhibitor comprises valproic acid, phenylbutyrate, or trichostatin A.